EUCTR2016-004303-32-NL
Active, not recruiting
Phase 1
ASsesment of Platelet function and Inhibition in patients Recovering from severe INfection - ASPIRIN-trial
VU university medical center0 sites62 target enrollmentApril 13, 2017
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Hyperaggregability of thrombocytes triggered by severe infection (i.e. pneumonia or invasive urinary tract infection or a cutaneous infection).
- Sponsor
- VU university medical center
- Enrollment
- 62
- Status
- Active, not recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •In order to be eligible to participate in the main\-trial, a subject must meet all of the following criteria:
- •Primary clinical diagnosis of pneumonia
- •Primary clinical diagnosis of invasive urinary tract infection
- •Primary clinical diagnosis of cutaneous infection
- •18 years or older on the date of hospital presentation
- •Hospitalization for at least 24 hours
- •Having received at least 1 dose of antibiotics within 48 hours of admission.
- •In order to be eligible to participate in the sub\-study, a subject must meet all of the following criteria:
- •Primary clinical diagnosis of pneumonia
- •Primary clinical diagnosis of invasive urinary tract infection
Exclusion Criteria
- •A potential subject who meets any of the following criteria will be excluded from participation in the main\-trial:
- •\-Active metastatic cancer (c.q. malignancy)
- •\-Allergy to salicylate
- •\-Platelet count \<120\*109/l
- •\-History of non\-traumatic major bleeding
- •\-Known bleeding diathesis
- •\-Conditions which require antiplatelet therapy
- •\-Usage of antiplatelet therapy
- •\-Surgery 1 month prior to diagnosis
- •\-Currently pregnant
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
ASsesment of Platelet function and Inhibition in patients Recovering from severe INfectionAcute myocardial infarctionHeart attack10011082NL-OMON50157Vrije Universiteit Medisch Centrum97
Recruiting
Not Applicable
Platelet-activation and optimal inhibition in patients with Atrial Fibrillation undergoing LAA closure; The POPULAR-LAAO trialAfibAtrial fibrillation10007521NL-OMON49947Sint Antonius Ziekenhuis120
Completed
Not Applicable
Inhibitory efficacy in platelet aggregation and pharmacokinetics of single oral administration of 300mg clopidogrel and 20mg prasugrelIschemic heart diseases with PICJPRN-UMIN000014161Kazuo Umemura Center for clinical research Hamamatsu University Hospital50
Not yet recruiting
Phase 4
The magnitude of platelet inhibition and the pharmacokinetics of a 600 mg loading dose of clopidogrel, in different patient categories (stable angina versus acute-coronary syndromes versus ST-elevated myocardial infarction).patients with a history of a stent thrombosis1003553410011082NL-OMON33697Cardiology200
Completed
Phase 2
A Study of Acute Coronary Syndrome PatientsCTRI/2010/091/000348Eli Lilly210